# Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma

> **NCT00483262** · PHASE1,PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 63 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** CCI-779
- **DRUG:** Bortezomib

## Key facts

- **NCT ID:** NCT00483262
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2011-01
- **Final completion:** 2012-02
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2013-11-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00483262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00483262, "Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT00483262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*